Technology | March 06, 2015

ACC Guideline App Upgrade Includes Full Set of Prevention Guidelines

App provides mobile access to guidelines, tools for treatment, heart disease prevention information

ACC, Guideline App, prevention, atrial fibrillation, clinical decision support

March 6, 2015 — The American College of Cardiology (ACC) has launched version 2.0 of their Guideline Clinical App. With the addition of the healthy lifestyle and obesity guidelines, the app now contains the full set of clinical prevention guidelines released by ACC/American Heart Association in 2013. These additions expand the collection of clinical guidelines in the app, which already includes guidelines on assessment of cardiovascular risk, treatment of blood cholesterol, atrial fibrillation, heart failure and valvular heart disease.

ACC’s Guideline Clinical App was developed to serve as a mobile home for all ACC/AHA guideline content and related tools. It includes an executive summary and top 10 points for each guideline, as well as a collection of interactive tools such as dosing calculators, scoring tools and algorithms useful to clinicians in determining recommended care

The original version of the app was launched in November 2014, with a second content release in December 2014. Version 2.0 of the app is part of a plan to continuously add guideline content, upgrade functionality and roll out fixes in response to user feedback. More guideline content and improvements are planned throughout 2015. ACC is conducting an impact and evaluation study to help inform future plans for the app. 

The ACC Guideline Clinical App is available for free and can be downloaded to a tablet or smartphone from iTunes and GooglePlay. 

For more information: www.acc.org


Related Content

News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
News | Atrial Fibrillation

December 22, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home December 22, 2023
Home
News | Atrial Fibrillation

December 14, 2023 — Medtronic plc, a global leader in healthcare technology, today announced that the United States Food ...

Home December 14, 2023
Home
Subscribe Now